Pituitary Hormone Infusion Pump Project

Reshaping Health Professional Training Pituitary Hormone Infusion Pump Project


Carry out the cooperation between the medical and engineering communities and realize commercialization.


Idiopathic hypogonadotropin hypogonadism (IHH) is caused by the impaired neuron function of the congenital hypothalamus gonadotropin releasing hormone (GnRH), the dysfunction of the GnRH synthesis, secretion and function. All these result in decreased secretion of gonadotropin by pituitary gland, and then result in insufficient gonadal function, which is called IHH. It is also known as congenital hypogonadotropic hypogonadism (CHH). The clinical application of GnRH pulse therapy began in 1982 and is mainly used for the treatment of IHH. Meanwhile, the domestic GnRH pulse pump was developed and tested for clinical use. Due to technical restrictions, it cannot be used in clinical practice. At the beginning of the 21st century, the new pulse pump with micro motor technology and especially developed artificial intelligence control system has become significantly smaller in size and can be infused at required time and amount; The frequency and dose of infusion are adjustable; The pulse infusion is quick and accurate; The product is easy to operate with high safety. At present, the only similar product registered and marketed overseas is the CRONO FE micropulse infusion pump. Its drawback is that the device is not easy to hide from visibility and the portability is not good.


  • In June 2009, the clinical demand was raised.
  • In July 2009, the project was officially launched.
  • In December 2009, the first infusion pump was born.
  • In March 2010, clinical trials were launched
  • In March 2012, the product was approved by SFDA and obtained the product registration certificate.


  1. In March 2012, the registration certificate was obtained.
  2. In January 2014, the invention patent was granted.
  3. In September 2014, the project was certified as Shanghai High-tech Achievement Commercialization Project.
  4. As of the end of 2018, the product has covered more than 180 domestic hospitals, and more than 140 babies have been successfully born after the use of this product in China.